Hepatic Cirrhosis Market

Key Highlights

• The Hepatic Cirrhosis market is expected to strengthen as awareness of the disease increases and more effective interventions are being developed.
• The leading Hepatic Cirrhosis Companies working in the market include NGM Biopharmaceuticals Inc, Conatus Pharmaceuticals Inc, Grifols Therapeutics LLC, Norgine, Mallinckrodt, Intercept Pharmaceuticals, and others

Request for unlocking the CAGR of the Hepatic Cirrhosis Market

DelveInsight’s “Hepatic Cirrhosis – Market Insights, Epidemiology, and Market Forecast – 2032” report delivers an in-depth understanding of the Hepatic Cirrhosis, historical and forecasted epidemiology as well as the Hepatic Cirrhosis market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

The Hepatic Cirrhosis market report provides current treatment practices, emerging drugs, the Hepatic Cirrhosis market share of the individual therapies, and current and forecasted Hepatic Cirrhosis market size from 2019 to 2032, segmented by the seven major markets. The report also covers current Hepatic Cirrhosis treatment practices/algorithms and 2023 hepatic cirrhosis unmet needs to curate the best of the opportunities and assess the underlying potential of the market.

Hepatic Cirrhosis Treatment Market

The hepatic cirrhosis treatment market is witnessing significant growth due to the rising prevalence of liver diseases and the increasing demand for effective therapeutic options. Hepatic cirrhosis, characterized by the progressive scarring of the liver, is a serious condition that can lead to liver failure if left untreated. The market is driven by the introduction of advanced treatment modalities, including liver transplantation, pharmacological interventions, and minimally invasive procedures. DelveInsight’s Hepatic Cirrhosis market report gives a thorough understanding of Hepatic Cirrhosis by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis, and treatment. 

Hepatic Cirrhosis Overview

Hepatic Cirrhosis is a late-stage liver disease in which healthy liver tissue is replaced with scar tissue and the liver is permanently damaged. Many types of liver diseases and conditions injure healthy liver cells, causing cell death and inflammation. This is followed by cell repair and finally tissue scarring as a result of the repair process. The scar tissue blocks the flow of blood through the liver and slows the liver’s ability to process nutrients, hormones, drugs, and natural toxins. It also reduces the production of proteins and other substances made by the liver. Cirrhosis eventually keeps the liver from working properly. Late-stage cirrhosis is life-threatening.

In the developed world, the most common causes of cirrhosis are hepatitis C virus (HCV), alcoholic liver disease, and nonalcoholic steatohepatitis (NASH), while hepatitis B virus (HBV) and HCV are the most common causes in the developing world. Other causes of cirrhosis include autoimmune hepatitis, primary biliary cholangitis, primary sclerosing cholangitis, hemochromatosis, Wilson disease, alpha-1 antitrypsin deficiency, Budd-Chiari syndrome, drug-induced liver cirrhosis, chronic right-sided heart failure.

The classification of liver cirrhosis is determined according to the appearance of symptoms: liver cirrhosis resulting in obvious symptoms such as jaundice, ascites (accumulation of fluid in the abdomen), and hepatic encephalopathy (confusion and coma) is called decompensated cirrhosis, whereas liver cirrhosis that does not produce these symptoms is called compensated cirrhosis. 

Cirrhosis can lead to many complications, some of which happen because the liver is no longer able to do these jobs well, and some because blood flow through the liver is disrupted. The major complications of cirrhosis include esophageal varices and variceal hemorrhage, ascites (abdominal swelling), infections of the abdominal cavity, hepatic encephalopathy, hepatorenal syndrome, and lung and heart complications, among others.

Hepatic Cirrhosis Diagnosis

Liver cirrhosis is a disease that causes a hardening of the organ. Nodules and irregularities form both inside and on the outer surface of the liver; these changes can be detected through an ultrasonic examination or CT scan. Because the function of the liver only decreases gradually, liver cirrhosis often goes undetected and unnoticed. Because of this, it is important to have regular examinations.

Imaging tests include Abdominal ultrasound, Elastography, Body magnetic resonance imaging (MRI), Magnetic resonance cholangiopancreatography (MRCP), Biopsy, and others,

Hepatic Cirrhosis Treatment

Treatment strategies in cirrhosis may vary depending on the disease stage as well as the underlying etiology. Broadly, the goals of treatment for compensated cirrhosis are to slow, halt or reverse the progression of fibrosis and prevent decompensation events, whereas for decompensated cirrhosis the focus is on preventing further decompensation and death (e.g., by improving liver function) and treating complications related to portal hypertension. 

The US Food and Drug Administration approved EPCLUSA to treat adult patients with chronic hepatitis C virus (HCV) both with and without cirrhosis. For patients with moderate to severe cirrhosis (decompensated cirrhosis), EPCLUSA is approved for use in combination with the drug ribavirin.

Recent Developmental Activities in the Hepatic Cirrhosis Treatment Landscape

• On June 2023, Grifols Therapeutics LLC announced a study of phase 3 clinical trials for Albutein 20% Injectable Solution. This is a clinical study that falls under phase 3, involving multiple medical centers. It is designed as a randomized, controlled, parallel-group trial, and is conducted openly without blinding. The primary objective of this study is to assess the effectiveness of standard medical treatment (SMT) in combination with Albutein 20% administration, compared to SMT alone, in individuals diagnosed with decompensated cirrhosis and ascites.
• On June 2023, AstraZeneca announced a study of phase 2 clinical trials for  zibotentan (dose B) + dapagliflozin and Placebo (matching zibotentan capsule & matching dapagliflozin tablet). This study consists of two phases (Phase IIa and Phase IIb) and takes place at multiple centers. It is a randomized, double-blind, placebo-controlled trial conducted in parallel groups. The primary objective is to evaluate the effectiveness, safety, and tolerability of a combination treatment involving zibotentan and dapagliflozin, as well as dapagliflozin monotherapy, compared to a placebo. The study specifically targets participants diagnosed with cirrhosis who exhibit signs of portal hypertension.

Hepatic Cirrhosis Epidemiology 

The Hepatic Cirrhosis epidemiology section provides insights into the historical and current Hepatic Cirrhosis patient pool and forecasted trends for the seven individual major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Hepatic Cirrhosis report also provides the prevalent patient pool, its trends, and assumptions undertaken.

Key findings

The study by Scaglione et al. (2015) aimed to estimate the prevalence of Cirrhosis in the general US population, determine characteristics of affected Americans with a focus on health disparities, and calculate excess mortality attributable to Cirrhosis. National Health And Nutrition Examination Survey data conducted between 1999 and 2010 were used to estimate Cirrhosis prevalence and factors associated with Cirrhosis. The prevalence of cirrhosis in the US was approximately 0.27%, corresponding to 633,323 adults. Sixty-nine percent reported that they were unaware of having liver disease.

The Hepatic Cirrhosis epidemiology covered in the report provides historical as well as forecasted Hepatic Cirrhosis epidemiology [segmented as Total Prevalent Cases of Hepatic Cirrhosis, Gender-specific Cases of Hepatic Cirrhosis, Age-specific Cases of Hepatic Cirrhosis, and Etiology-specific Cases of Hepatic Cirrhosis] in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan from 2019 to 2032.

Country-wise Hepatic Cirrhosis Epidemiology

The epidemiology segment also provides the Hepatic Cirrhosis epidemiology data and findings across the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Hepatic Cirrhosis Drug Chapters

The drug chapter segment of the Hepatic Cirrhosis report encloses a detailed analysis of Hepatic Cirrhosis marketed drugs and late-stage (Phase III and Phase II) Hepatic Cirrhosis pipeline drugs. It also helps understand the Hepatic Cirrhosis clinical trials details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

Emerging Hepatic Cirrhosis Drugs

The report details the emerging Hepatic Cirrhosis therapies under the late and mid-stage of development for Hepatic Cirrhosis treatment.

Hepatic Cirrhosis Market Outlook

The Hepatic Cirrhosis market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Hepatic Cirrhosis market trends by analyzing the impact of current therapies on the market, hepatic cirrhosis unmet needs, and demand for better technology.

This segment gives a thorough detail of the Hepatic Cirrhosis market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need for the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Hepatic Cirrhosis market in the 7MM is expected to witness a major change in the study period 2019–2032.

Key findings

This section includes a glimpse of the Hepatic Cirrhosis market in the 7MM.

The United States: Hepatic Cirrhosis Market Outlook

This section provides the total Hepatic Cirrhosis market size and market size by therapies in the United States.

EU4 and the United Kingdom: Hepatic Cirrhosis Market Outlook

The total Hepatic Cirrhosis market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.

Japan: Hepatic Cirrhosis Market Outlook

The total Hepatic Cirrhosis market size and market size by therapies in Japan are also mentioned.

Hepatic Cirrhosis Drug Uptake

This section focuses on the rate of uptake of the potential drugs recently launched in the Hepatic Cirrhosis market or expected to get launched in the market during the study period 2019–2032. The analysis covers the Hepatic Cirrhosis market uptake by drugs, patient uptake by therapies, and sales of each drug.  

This will help in understanding the Hepatic Cirrhosis drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on market share and size, which again will be useful in investigating factors important in the market uptake and in making financial and regulatory decisions.

Hepatic Cirrhosis Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Hepatic Cirrhosis companies involved in developing targeted therapeutics.

Development Activities

The report covers detailed information on collaborations, acquisitions, and mergers, licensing patent details, and other information for Hepatic Cirrhosis emerging therapies.

Hepatic Cirrhosis Reimbursement Scenario

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL Views

To keep up with current epidemiology and market trends, we take KOLs and SMEs' opinions working on the Hepatic Cirrhosis domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies and treatment patterns along with Hepatic Cirrhosis market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the hepatic cirrhosis unmet needs.

Competitive Intelligence Analysis

We perform competitive and market intelligence analysis of the Hepatic Cirrhosis market by using various competitive intelligence tools that include – SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Hepatic Cirrhosis Market Report Scope

• Descriptive overview of Hepatic Cirrhosis, disease overview, patient journeys, treatment algorithms, diagnosis, and currently available therapies
• Comprehensive insight into the Hepatic Cirrhosis epidemiology and forecasts in the 7MM
• An all-inclusive account of both the current and emerging therapies for Hepatic Cirrhosis, along with the assessment of new therapies, expected to have an impact on the current treatment landscape
• Exhaustive analysis of the Hepatic Cirrhosis market; historical and forecasted covering drug outreach in the 7MM
• Detailed patient-based Hepatic Cirrhosis market forecasting determines the trends shaping and driving the global Hepatic Cirrhosis market

Hepatic Cirrhosis Market Report Highlights

• In the coming years, the Hepatic Cirrhosis market is set to change due to the rising awareness of the disease and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
• The Hepatic Cirrhosis companies and academics are working to assess challenges and seek opportunities that could influence Hepatic Cirrhosis R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition   
• Hepatic Cirrhosis companies are involved in developing Hepatic Cirrhosis therapies. The launch of emerging therapies will significantly impact Hepatic Cirrhosis market
• A better understanding of Hepatic Cirrhosis pathogenesis will also contribute to the development of novel therapeutics for Hepatic Cirrhosis
• Our in-depth analysis of the Hepatic Cirrhosis pipeline assets across different stages of development (Phase III and Phase II), emerging trends, and comparative analysis of pipeline products with detailed hepatic cirrhosis clinical trials profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Hepatic Cirrhosis Report Insights

• Patient-Based Hepatic Cirrhosis Market Forecasting 
• Therapeutic approaches
• Hepatic Cirrhosis pipeline analysis
• Hepatic Cirrhosis market size and trends
• Hepatic Cirrhosis market opportunities
• Impact of upcoming therapies

Hepatic Cirrhosis Report Key Strengths

• 10 years Hepatic Cirrhosis Market Forecast
• The 7MM Coverage
• Hepatic Cirrhosis epidemiology segmentation
• Key cross competition
• KOL views
• Hepatic Cirrhosis drugs uptake

Hepatic Cirrhosis Report Assessment

• Current Hepatic Cirrhosis treatment market practices
• Hepatic Cirrhosis Unmet needs
• Hepatic Cirrhosis pipeline product profiles
• Hepatic Cirrhosis market attractiveness

Key Questions

Hepatic Cirrhosis treatment market insights:

• What would be the Hepatic Cirrhosis market growth till 2032, and what will be the resultant market size in 2032?
•  What was the Hepatic Cirrhosis drug class share (in percentage) distribution in 2019, and how would it look in 2032?
• What would be the Hepatic Cirrhosis total market size and market size by therapies across the 7MM during the forecast period (2023–2032)?
• What are the key findings of the market across the 7MM, and which country will have the largest Hepatic Cirrhosis market size during the forecast period (2023–2032)
• How would the unmet needs affect the Hepatic Cirrhosis market dynamics and subsequent analysis of the associated trends?

Hepatic Cirrhosis Epidemiology Insights:

• What are the disease risk, burden, and regional/ethnic differences of Hepatic Cirrhosis?
• What is the historical and forecasted Hepatic Cirrhosis patient pool in the 7MM, and where can one observe the highest patient population and growth opportunities? 
• What are the key factors driving the epidemiology trends for the seven major markets covering the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan?

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies

• What are the current treatment guidelines and treatment options, in addition to approved therapies for Hepatic Cirrhosis in the United States, Europe, and Japan?
• What are the key collaborations (Industry–Industry, Industry-Academia), mergers and acquisitions, and licensing activities related to Hepatic Cirrhosis therapies?
• What are the recent novel therapies, targets, mechanisms of action, and technologies being developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Hepatic Cirrhosis and its status, along with the challenges faced?

Reasons to Buy

• The patient-based market forecast analysis will help in developing business strategies by understanding trends shaping and driving the Hepatic Cirrhosis market
• Organize sales and marketing efforts by identifying the best opportunities for Hepatic Cirrhosis in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan
• Identification of strong upcoming players in the market that will help devise strategies that will help in getting ahead of competitors